VBI Vaccines Provides Update on GBM Program and Announces Upcoming Conference Call
23 avr. 2019 08h00 HE
|
VBI Vaccines, Inc.
10mcg dose selected to advance into Part B of Phase 1/2a study of VBI-1901 in recurrent GBMExpanded data from Part A of the Phase 1/2a study of VBI-1901 selected for poster presentation at...